These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10991664)

  • 1. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
    Chase TN; Oh JD; Konitsiotis S
    J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E
    Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
    Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
    Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
    Oh JD; Vaughan CL; Chase TN
    Brain Res; 1999 Mar; 821(2):433-42. PubMed ID: 10064831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
    Oh JD; Geller AI; Zhang Gr; Chase TN
    Brain Res; 2003 May; 971(1):18-30. PubMed ID: 12691833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
    Chase TN; Bibbiani F; Bara-Jimenez W; Dimitrova T; Oh-Lee JD
    Neurology; 2003 Dec; 61(11 Suppl 6):S107-11. PubMed ID: 14663022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal glutamatergic mechanisms and extrapyramidal movement disorders.
    Chase TN; Bibbiani F; Oh JD
    Neurotox Res; 2003; 5(1-2):139-46. PubMed ID: 12832228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
    Bibbiani F; Oh JD; Petzer JP; Castagnoli N; Chen JF; Schwarzschild MA; Chase TN
    Exp Neurol; 2003 Nov; 184(1):285-94. PubMed ID: 14637099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
    Chase TN; Oh JD
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S86-91. PubMed ID: 11052225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neostriatal mechanisms in Parkinson's disease.
    Chase TN; Oh JD; Blanchet PJ
    Neurology; 1998 Aug; 51(2 Suppl 2):S30-5. PubMed ID: 9711978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.
    Blandini F; Armentero MT
    Expert Opin Investig Drugs; 2012 Feb; 21(2):153-68. PubMed ID: 22233485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pharmacological strategies for motor complications in Parkinson's disease.
    Konitsiotis S
    Expert Opin Investig Drugs; 2005 Apr; 14(4):377-92. PubMed ID: 15882115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN
    Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.